| Benign prostate hyperplasia (BPH) is an extremely common prostate disease in more than 70% of men over the age of 60, which can lead to a lot of signs and complications in this population. And yet the pathogenesis is still obscure. Prostatic carcinoma(Pca) is malignancy which has taken the second incidence of the diseases in Occident men and its increasing rate of the incidence has taken the first place in Urological and procreation malignancy in China. Prostatic carcinoma is characterized with the latency and high incidence. In China, 25 percent of people over 70 years old suffer prostatic carcinoma, but only a few can become the patients with clinical cancer. In therapy, chemical drugs are difficult to enter into prostatic tissue, and more prostatic carcinoma will metastasis when patients have clinical symptom. Therefore, surgery has bad effects.Today endocrine therapy can improve patients' symptom and lessen the pain of the patients, however, it can't prolong survival time, which calls for new ways to treat prostatic carcinoma. The gowth of prostate is gradulated by many multi peptide growth factors, including basic fibroblast growth factor (b-FGF) which is an important factor to promote blood vessel growth and cell mitosis and which plays an important role in the growth, proliferation, differentiation and blood vessel formation of the prostate cells. Some depressors of basic fibroblast growth factor have been applied to treat benign prostate hyperplasia and prostatic carcinoma , and have gained goodeffects. The present study employed RNA dot blot hybridization and immunohistochemistry to explore the expression of basic fibroblast growth factor in normal prostate tissue (NP) ,benign prostate hyperplasia(BPH) and prostatic carcinoma(Pca), aiming to study possible role of b-FGF.Aim: To investigate the expression of basic fibroblast growth factor (b-FGF) in human normal prostate tissue (NP) ,benign prostatic hyperplasia (BPH) & prostatic carcinoma(Pca) and the relationship between the b-FGF and the graduation of prostatic hyperplasia, pathologic grading as well as clinical stages of prostatic carcinoma to lay the foundation for further therapeutic experiment. Mean while, to investigate if b-FGF can be a marker of prostatic carcinoma(Pca).Methods: The b-FGF plasmid were conversed, amplified and extracted in specimens of 30 normal prostate tissues (NP), 58 BPH and 56 Pea tissues. The b-FGF plasmid that was acquired were cut by EcoR I and Hind II encyme to retrieve probe fragments,which were marked through fluorescein-marking-kit-random- primer technique. The cell ribonuclunc acid(RNA) was extracted by the fluorescein isothiocyanate one-stage technique and the same concentration of RNA was used to point membran for RNA dot blot hybridization.The kit radiat self-developing method was used for detection. The blotch averge absorbing light degree on the developing film was measured by the computer image analysis technique. The expression and distribution of b-FGF were examined by LSAB way.Results: l.The result of RNA dot blot hybridization: The b-FGF mRNA was expressed weakly in normal prostate tissues (NP) but was expressed strongly in prostatic hyperplasia (BPH) and prostatic carcinoma (Pca). The expressions of b-FGF mRNA in BPH and Pca tissues were significantly higher than those in normal prostate tissues(P<0.01).There was significant difference at the expression of b-FGF mRNA between BPHand Pca tissues(P < 0.05). No significant difference was found in the expression of b-FGF mRNA in BPH specimens of different degrees by analysis of variance. No significant difference was also found in the expression of b-FGF mRNA in specimens of different pathologic grading as well as clinical stages of prostatic carcinoma by analysis of variance.2. The result of immunohistochemistry: In specimens of 30 normal prostate tissues(NP), basic fibroblast growth factor (b-FGF) were weakly male staining which mainly located in cytoplasm of interstitial cell and the male expression rate was 10.0% (3/30) . In specimens of B...
|
PDF Full Text Request